BioAtla, Inc. (BCAB) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

sites on hold. We do appreciate your patience and ask that you continue to stand by. I'm © transcript Emily Beynon . . . . . . ¶¶ Please stand by, your program is about to begin. If you need assistance during your conference today, please press star zero. Good day everyone. and welcome to today's BioATLA second quarter 2024 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Bruce Mackel of LifeSci Advisors. Thank you, Operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO, and Co-Founder, and Richard Waldron, Chief Financial Officer. Following today's call, Dr. Eric Sievers, Chief Medical Officer, and Sherry Lydick, Chief Commercial Officer, will join Jay and Rick in a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the second quarter ended June 30, 2024. A copy of the press release and corporate presentation are available on the company's website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtlas business plans and prospects and whether its clinical trials will support registration, plans to form collaborations and other strategic partnerships for selected assets, achievement of milestones, results, conduct, progress, and timing of its research and development programs and clinical trials, expectations with...